SAVIENT PHARMACEUTICALS INC | 0,46 Euro | +0,004 +0,88 % | |
| WKN: 813149 ISIN: US80517Q1004 Ticker-Symbol: BY7 | Frankfurt | 20.05.13 | 08:01 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 15.05. | Savient Pharmaceuticals Down 14.1%, Shares Slide into the Red | 9 | SmarTrend | |
| 15.05. | SAVIENT PHARMACEUTICALS INC - 10-Q, Quaterly Report | 5 | SEC Filings | |
| 15.05. | SAVIENT PHARMACEUTICALS INC - 8-K, Current Report | 9 | SEC Filings | |
| 15.05. | Savient Pharmaceuticals Reports First Quarter 2013 Financial Results | 23 | PR Newswire | |
| BRIDGEWATER, N.J., May 15, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2013. Net sales of KRYSTEXXA®(pegloticase)... Mehr lesen zu: Savient Pharmaceuticals Reports First Quarter 2013 Financial Results | ||||
| 25.03. | Savient Pharmaceuticals: Is Anything Left? | 18 | Seeking Alpha | |
| 19.03. | Savient Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript | 4 | Seeking Alpha | |
| 19.03. | Investors look to Lighten Up on Shares of Savient Pharmaceuticals, Shares Down 10.7% | 6 | SmarTrend | |
| 19.03. | Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results | 36 | PR Newswire | |
| BRIDGEWATER, N.J., March 19, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months and full year ended December 31, 2012. Savient ended... Mehr lesen zu: Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results | ||||
| 26.02. | Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013 | 47 | PR Newswire | |
| BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end 2012 financial results will be released... Mehr lesen zu: Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013 | ||||
| 21.02. | Savient to Promote Sobi's Kineret | 7 | Zacks | |
| 19.02. | Sobi, Savient (SVNT) Enter Kineret Co-Promotion Agreement | 4 | StreetInsider.com | |
| 19.02. | Swedish Orphan Biovitrum AB (publ): Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret (anakinra) in the U.S. | 66 | Thomson Reuters ONE | |
| CONTACT: Swedish Orphan Biovitrum (Sobi) ABAlan RaffenspergerChief Operating Officer+46 8 697 20 90 Savient Pharmaceuticals, Inc. John P. HamillSenior Vice President and Chief Financial... Mehr lesen zu: Swedish Orphan Biovitrum AB (publ): Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret (anakinra) in the U.S. | ||||
| 19.02. | Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret (anakinra) in the U.S. | 47 | PR Newswire | |
| STOCKHOLM and BRIDGEWATER, N.J., Feb. 19, 2013 /PRNewswire/ --Sobi (STO: SOBI) and Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that they have entered into an agreement for the co-promotion... Mehr lesen zu: Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret (anakinra) in the U.S. | ||||
| 14.02. | Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success / RDInvesting Provides Stocks Research on Alexza Pharmaceuticals and Savient Pharmaceuticals | 62 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 02/14/13 -- A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ... Mehr lesen zu: Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success / RDInvesting Provides Stocks Research on Alexza Pharmaceuticals and Savient Pharmaceuticals | ||||
| 23.01. | Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash / Five Star Equities Provides Stock Research on Corcept Therapeutics and Savient Pharmaceuticals | 77 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 01/23/13 -- Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology... Mehr lesen zu: Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash / Five Star Equities Provides Stock Research on Corcept Therapeutics and Savient Pharmaceuticals | ||||
| 13.01. | Savient Pharma: The Ultimate Biotech Option | 30 | Seeking Alpha | |
| 10.01. | Savient Pharmaceuticals' CEO Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript) | 4 | Seeking Alpha | |
| 08.01. | Savient's KRYSTEXXA (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout | 81 | PR Newswire | |
| BRIDGEWATER, N.J. and DUBLIN, Jan. 8, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and its wholly owned subsidiary, Savient Pharma Ireland Ltd., today announced that the European... Mehr lesen zu: Savient's KRYSTEXXA (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout | ||||
| 08.01. | Savient Pharma Elects Genzyme's David Meeker to Board | 6 | Benzinga.com | |
| 08.01. | Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors | 50 | PR Newswire | |
| BRIDGEWATER, N.J., Jan. 8, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that David Meeker, M.D., President and Chief Executive Officer of Genzyme, a Sanofi Company... Mehr lesen zu: Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| CELL THERAPEUTICS | 0,886 | +1,03 % | Cell Therapeutics to Present at Upcoming Investor Conferences |
| VICAL | 2,752 | -0,18 % | Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma |
| GERON | 0,856 | -2,73 % | Arena Pharma, Celgene, Incyte, Spectrum Pharma, and Geron Under StockCall's Microscope |
| EXELIXIS | 3,509 | -1,21 % | Programs by the FDA Designed to Speed Up Approval Process for Critical Drugs a Key Factor in Biotech's Industry Success / Five Star Equities Provides Stock Research on Exelixis and Lexicon Pharmaceuticals |
| KERYX BIOPHARMACEUTICALS | 6,231 | -0,06 % | Keryx Biopharmaceuticals Earnings Hindsight: Up 0.6% in Last 13 Days |
